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Abstract
The RON receptor tyrosine kinase regulates epithelial cell homeostasis and tumorigenesis by
transducing multiple signals through its functional domains. The present study was to determine
the significance of the entire C-terminus in RON or its variant RON160-mediated activities related
to cell motility and tumorigenesis. Analysis of protein phosphorylation revealed that elimination of
the entire C-terminus significantly impairs the ligand-dependent or independent RON or RON160
phosphorylation and dimerization. Phosphorylation of downstream signaling proteins such as Erk1/
2, AKT, and p38 MAP kinase was also diminished in cells expressing the C-terminus-free RON or
RON160. These dysfunctional activities were accompanied with the inability of truncated RON or
RON160 to mediate cytoplasmic β-catenin accumulation. Functional analysis further demonstrated
that truncation of the C-terminus significantly impairs RON or RON160-mediated cell
proliferation, morphological changes, and cellular migration. Significantly, oncogenic RON160-
mediated tumor growth in athymic nude mice was lost after the deletion of the C-terminus. Thus,
the C-terminus is a critical component of the RON receptor. The entire C-terminus is required
for RON or RON160-mediated intracellular signaling events leading to various cellular activities.
Introduction
The RON (Recepteur d'Origine Nantaise) receptor tyro-
sine kinase is the product of the c-RON proto-oncogene
[1] and the high affinity receptor for macrophage-stimu-
lating protein (MSP) [2,3], also known as hepatocyte
growth factor like protein [4]. RON is mainly expressed in
cells of epithelial origin and required for embryonic
development [5,6]. Biochemically, RON is first synthe-
sized as a single-chain precursor with 1400 amino acids
[1-3]. Proteolytic conversion of pro-RON into a mature
RON is a step necessary for MSP binding and biological
activities [1-3]. This process is mediated by proteases at
the cleavage site of Pro304-Lys305, resulting in a 180 kDa
heterodimeric protein with a 40 kDa extracellular α-chain
and a 145 kDa transmembrane β-chain [1-3], both chains
are linked by a disulphide bound [1-3]. Several functional
domains have been identified in the RON protein. In the
RON β-chain, the extracellular sequences contain a N-ter-
minal semaphoring (Sema) domain followed by a plexin-
semaphorin-integrin (PSI) motif and four IPT (Immu-
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noglobulin, Plexin, and Transcription factor) domains
[1,7]. The sema domain is responsible for MSP binding
and receptor dimerization [8]. The IPT domains are essen-
tial in regulating RON maturation and kinase activities
[9,10]. Deletion of the first or fourth IPT domain through
the mRNA splicing processes has been linked to constitu-
tive RON phosphorylation and impaired receptor matura-
tion [9,11]. The juxtamembrane domain, tyrosine kinase
domain and C-terminus are three functional structures in
the intracellular sequences of the RON β-chain [1,7].
Deletion of the juxtamembrane domain has been shown
to enhance RON phosphorylation [12]. In contrast, dele-
tion of last 46 amino acids in the kinase domain severely
impairs MSP-induced RON phosphorylation and tyrosine
kinase activities [13]. The C-terminus contains a bidentate
motif (-Y1353VQLPATY1360MNL-) and additional determi-
nants [14,15]. Both positive and negative effects of the C-
terminus have been demonstrated by in vitro and in vivo
studies [14-16]. Thus, the functional domains are criti-
cally important in regulating RON-mediated activities.
Studies of RON in epithelial carcinogenesis have recently
demonstrated that RON is highly expressed in various pri-
mary tumor samples including breast, colon, and pancre-
atic cancers [17-19]. Overexpression has also been shown
to be associated with advanced clinical stages and poor
clinical outcomes [20-22]. One pathogenic feature associ-
ated with RON overexpression is the production of bio-
logically active RON variants [23]. These variants are
produced either by alternative mRNA splicing or by alter-
native mRNA initiation [24]. A typical example is
RON160 identified in primary colon cancer samples and
in established cell lines [11,23]. RON160 is derived from
an mRNA splicing transcript that has an in-frame deletion
of 109 amino acids coded by exons 5 and 6. These 109
amino acids constitute the first IPT domain in the RON β-
chain extracellular sequences [7,11]. RON160 has a
molecular mass of 160 kDa and is constitutively phospho-
rylated with increased kinase activities [11]. High levels of
Erk1/2, PI-3 kinase, and AKT activities are often observed
in RON160 expressing cells [11,23]. Expression of
RON160 results in transforming phenotypes in rodent
fibroblast and human colonic epithelial cells and causes
tumor growth in athymic nude mice [11,23-25]. Moreo-
ver, RON160 stimulates colonic cell morphological
changes and motilities characterized by epithelial to mes-
enchymal transition (EMT) [25-27]. Although the mecha-
nisms underlying RON160 mediated tumorigenesis are
currently unknown, it is believed that the tumorigenic
potential is attributed to its increased kinase activities
leading to enhanced intracellular signaling cascades.
Thus, RON overexpression, accompanied with generation
of tumorigenic RON variants, is a pathogenic factor con-
tributing to pathogenesis of various epithelial cells.
The present study was to determine the significance of the
entire C-terminus in regulating RON or RON160-medi-
ated biological activities. Previous studies have showed
that the C-terminal bidentate motif is essential in regulat-
ing RON kinase activities leading to increased cellular
functions [14,16]. However, biochemical analysis sug-
gests that the C-terminus plays a negative role in regulat-
ing RON kinase activities [15]. This is evident in
experiments showing that the C-terminus and the peptide
containing Y1353/Y1630  or substituted F1353/F1360  motif
strongly inhibit RON kinase activities [15]. In contrast,
experiments of tumorigenesis mediated by certain RON
mutants suggest that the C-terminal Y1353/Y1360 motif is
not required for tumorigenesis [28]. The RON mutant
(M1254T) with F1353/F1360 substitutions is capable of medi-
ating tumor growth in nude mice, which is comparable to
the control RON mutant without Y1353/Y1360 substitution
[28]. Considering the pathogenic significance of RON160
in colonic epithelial cells, we wanted to determine the
importance of the entire C-terminus in RON or RON160-
mediated activities. By generating cDNA encoding human
RON or RON160 free of the C-terminus, we demonstrated
that the entire C-terminus is critically important in regu-
lating RON/RON160 kinase activities and essential for
RON or RON160-mediated biological activities.
Materials and methods
Cells and reagents
NIH3T3 cells expressing RON or RONΔ160 were used as
previously described [23]. Mouse monoclonal antibodies
(mAb) Zt/g4 and Zt/c1 specific to RON extracellular
sequences) and rabbit polyclonal IgG antibodies
(R*5029, specific to the RON C-terminal peptide) were
used as previously described [23,29]. Mouse anti-phos-
photyrosine (PY-100), goat or rabbit IgG antibodies spe-
cific to regular or phosphor- Erk1/2 (p44/42), p38 MAP
kinase, AKT, GSK-3β, and β-catenin were from Cell Sign-
aling Inc (Beverly, MA). Normal mouse IgG and goat anti-
mouse IgG conjugated with FITC were from Jackson Lab-
oratories (Maine).
Generation and expression of RON or RON160 variant 
free of the C-terminal tail
The RON C-terminus contains 55 amino acids starting
from Ser1346, the first amino acids after the tyrosine kinase
domain, and ending at Thr1400, the last amino acid of
RON [1,7]. Using RON or RON160 cDNA as the template,
the RON C-terminus-free (cf) and RON160-cf cDNA free
of the entire C-terminal sequences were generated by PCR
techniques and confirmed by DNA sequence analysis. The
cDNA was inserted into the expression vector pcDNA3.1
(Invitrogen) and stable NIH3T3 cells expressing RON-cf
or RON160-cf were established by DNA transfection tech-
niques [23]. Positive cells were isolated by incubation
with anti-RON mAb Zt/c1 followed by magnetic beadsJournal of Experimental & Clinical Cancer Research 2008, 27:55 http://www.jeccr.com/content/27/1/55
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conjugated with goat-anti-mouse IgG as previously
described [29].
Immunoprecipitation and Western blot analysis
Immunoprecipitation of RON or other proteins from cel-
lular lysates was performed using Zt/c1 or other mAb fol-
lowed by Western blot analysis as previously described
[23]. Briefly, cells (3 × 106 cells/sample) were lysed in the
lysis buffer as previously described [23]. Cellular proteins
were immunoprecipitated overnight with Zt/g4 or other
antibodies (2 μg mAb per sample) coupled with protein G
Sepharose beads. After washing, samples were boiled at
100°C for 4 min and then separated in 7% SDS-PAGE
under reduced condition. The proteins were transferred
into the membrane and blocked with 1% BSA in TBS-T
buffer. Western blot analysis was carried out using rabbit
IgG anti-RON or other specific antibodies followed by
HRP-conjugated second antibodies. The reaction was
developed with enhanced ECL reagents and analyzed by
the VersaDoc imagine system (Bio-Rad).
Biotinylation of cell surface protein
Due to lack of antibodies to detect RON-cf and RON160-
cf in Western blotting, the method of protein biotinyla-
tion was used to label RON-cf or RON160-cf on cell sur-
face (CalBiochem). Biotin-labeled proteins were
immunoprecipitated with mAb Zt/c1 and detected by
HPR-conjugated avidin in Western blot analysis.
Cell proliferation assays
T3-RON, -RON-cf, -RON160, or -RON160-cf cells (0.8 ×
104 cells/well) were seeded in a 96-well plate in triplicate
in DMEM with 5% FBS. NIH3T3 cells were used as the
control. RON agonistic mAb Zt/g4 (2 nM) was added
simultaneously after initiation of cell culture [29]. After
incubation for 5 days, the number of cells was counted as
previously described [23].
Cell surface immunofluorescent analysis
3T3-RON, -RON-cf, -RON160 and -RON160-cf cells were
incubated with mAb Zt/c1 (2 μg mAb per sample) fol-
lowed by FITC-coupled goat anti-mouse IgG. 3T3-RON
cells with normal mouse IgG served as the negative con-
trol. Labeled samples were analyzed for fluorescent inten-
sities by FACScan as previously described [29].
Assays for cell morphological changes and migration
3T3-RON, -RON-cf, -RON160 or -RON160-cf cells (1 ×
105 cells/well) were incubated in a 24-well plate, stimu-
lated with or without mAb Zt/g4 (2 nM) for 5 days, and
then photographed (magnification × 200). Parental
NIH3T3 cells were used as the control. The migration
assay was carried out as detailed previously [23]. Briefly,
cell monolayers were wounded by a plastic tip and then
treated with Zt/g4 (2 nM). After incubation for 48 h,
migrated cells in the wounded area were photographed
and measured.
In vivo tumorigenic assays
Experiments were performed as previously described [23].
The use of animals was apprived by the institutional ani-
mal usage committee of the Texas Tech University Health
Sciences Center (Approval number 0421). Briefly, 3T3-
RON160 or -RON160-cf cells were inoculated subcutane-
ously into the posterior flank of athymic nude mice (1 ×
106 cells per mouse in 0.2 ml PBS, three mice per group).
The tumor growth was monitored daily for 30 days.
Parental NIH3T3 and 3T3-RON cells were used as the con-
trol. The latency was determined as the period of time
required by tumors to reach a diameter of 0.5 cm [23].
Statistical analysis
Differences between control and experimental groups
were determined by student t test. The statistical differ-
ences at P < 0.05 were considered significant.
Results
Generation and expression of RON-cf and RON160-cf in 
NIH-3T3 cells
Previous studies have shown that F1353/F1360 substitutions
in the C-terminal bidentate motif do not affect MSP-
induced RON phosphorylation but impair cell migration
[16]. Other studies have found that the C-terminal tail
negatively regulates RON kinase activities [15]. To address
the importance of the entire C-terminus in RON or
RON160-mediated biological activities, the cDNA encod-
ing RON or RON160 free of the C-terminus was generated
by PCR techniques that eliminate the last 55 amino acids
(from Ser1346 to Thr1400) in the RON protein. The sche-
matic representation of RON, RON160, RON-cf, and
RON160-cf was presented in Fig. 1A. The DNA sequence
analysis confirmed that the truncated cDNA were cor-
rected generated as designed (data not shown). Upon
selection of stably transfected 3T3 cell lines, the expres-
sion of RON-cf or RON160-cf, along with RON or
RON160, was analyzed by the immunofluorescent cell
surface analysis. Results in Fig. 1B showed expression of
RON-cf and RON160-cf on the cell surface as evident by
Zt/g4 immunofluorescent detection. The levels of RON-cf
or RON160-cf were relatively lower than those of RON or
RON160 in expressed cells. These results suggest that
elimination of the c-terminus has no effect in the process
of RON or RON160 for the cell surface localization.
The C-terminal tail is required for spontaneous or induced 
phosphorylation of RON or RON160
To determine if the truncation of the C-terminus affects
RON or RON160 expression and phosphorylation, West-
ern blotting was first performed to determine the sizes of
RON-cf or RON160-cf. Results in Fig. 2A (top panel)Journal of Experimental & Clinical Cancer Research 2008, 27:55 http://www.jeccr.com/content/27/1/55
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Generation of C-terminus-free RON and RON160 and their expression in NIH3T3 cells Figure 1
Generation of C-terminus-free RON and RON160 and their expression in NIH3T3 cells: (A) Schematic represen-
tation of the RON, RON160 and their C-terminus-free variants. RON is composed of a 40 kDa α-chain and a 150 kDa β-chain. 
The β-chain has several domains including a sema domain, a PSI motif, four IPT units, followed by a transmembrane (TM) 
domain, a juxtamembrane domain, a tyrosine kinase (TK) domain, and a short C-terminal tail. The generation of C-terminus-
free RON or RON160 variants was carried out as detailed in Materials and Methods. (B) Cells (1 × 105 cells/sample) were 
incubated for 45 min at 4°C with mAb Zt/g4 (1 μg/sample) or normal mouse IgG (1 μg/sample) followed by goat anti-mouse 
IgG coupled with FITC. Immunofluorescent intensities were measured by FACSan. One of two experiments with similar 
results.
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showed the correct sizes of RON-cf and RON160-cf. Using
these cell lines, the effect of the C-terminal truncation on
RON or RON160 phosphorylation was determined using
the RON agonistic mAb Zt/g4 as the stimulant. Zt/g4 has
agonistic activities and is more potent than MSP [29]. As
shown Fig. 2A (middle panel), Zt/g4 induced RON phos-
phorylation in 3T3-RON cells but had no effect on 3T3-
RON-cf cells. In 3T3-RON160 cells, spontaneous phos-
phorylation was seen and further enhanced by Zt/g4 stim-
ulation. However, these effects were not observed in
RON160-cf cells. Similar results were also seen when cells
were stimulated with MSP (data not shown).
To address if the C-terminus was involved in RON dimer-
ization, a step required for phosphorylation, cells were
stimulated with Zt/g4 followed by cross-linking and West-
ern blot analysis. RON dimerization was seen in Zt/g4
stimulated cells evident by the appearance of high molec-
Effect of the C-terminal truncation on agonistic mAb Zt/g4-induced RON or RON160 phosphorylation and dimerization Figure 2
Effect of the C-terminal truncation on agonistic mAb Zt/g4-induced RON or RON160 phosphorylation and 
dimerization. (A) 3T3-RON or other cells (4 × 106 cells/sample) were stimulated with or without mAb Zt/g4 (2 nM) in 
serum-free conditions for 10 min. Half of the cells were biotinylated for cell surface proteins. Labeled RON, RON160, or their 
variants were immunoprecipitated with mAb Zt/c1 and detected in Western blotting using avidin-conjugated antibodies (top 
panel). The other half of the cells were lysed and immunoprecipitated by Zt/c1. Phosphorylated proteins were detected by 
mAb PY-100 (middle panel). To ensure equal amounts of samples used, cell lysates were directly analyzed for actin in Western 
blotting (bottom panel). (B) Cells were stimulated as above and then treated with a permeable cross-linker followed by cell 
surface biotinylation [13]. The proteins were immunoprecipitated and detected in Western blot analysis as described in (A). 
Data shown here are from one of three experiments with similar results.
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ular bands, but not in quiescent cells. Stimulation of
RON-cf did not cause any visible dimerization (Fig. 2B).
Similar results were also seen in RON160-cf cells (data not
shown). These results, together with those in Fig. 2A, sug-
gest that the C-terminus was required for ligand-depend-
ent or independent phosphorylation of RON or RON160.
Effect of C-terminal truncation on RON/RON160-
mediated activation of three signaling pathways
To determine if the C-terminus was involved in RON or
RON160-mediated downstream signaling events, phos-
phorylation of Erk1/2, Akt, and p38 MAP kinase was stud-
ied in 3T3-RON-cf and RON160-cf cells. As shown in Fig.
3A, Zt/g4 stimulation of 3T3-RON cells induced strong
Erk1/2 phosphorylation in a time-dependent manner.
High levels of AKT phosphorylation were also seen. The
Effect of the C-terminal truncation on RON or RON160-mediated activation of downstream signaling proteins Figure 3
Effect of the C-terminal truncation on RON or RON160-mediated activation of downstream signaling pro-
teins: Cells (2 × 106 cells/sample) were stimulated with RON agonistic mAb Zt/g4 (2 nM) in serum-free conditions for various 
times as indicated. Proteins (50 μg per lane) from cell lysates were subjected to Western blot analysis using antibodies specific 
to regular or phospho-p44/42, Akt, and p38 MAP kinase, respectively. Data shown here are from one of three experiments 
with similar results.
¶¶¶KKKQ0=WJ
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
¶¶¶KKKQ0=WJ
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
 
￿
￿
￿
￿
￿
￿
￿
￿
!
"
#
￿
￿
￿
￿
￿
￿
￿
￿
$
￿
￿
￿
￿
￿
￿
￿
￿
!
"
#
￿
￿
￿
￿
￿Journal of Experimental & Clinical Cancer Research 2008, 27:55 http://www.jeccr.com/content/27/1/55
Page 7 of 12
(page number not for citation purposes)
levels of p38 MAKP kinase phosphorylation were rela-
tively low. In 3T3-RON160-cf cells, truncation of the C-
terminus significantly reduces the Zt/g4-induced RON-
mediated Erk1/2 phosphorylation although low levels of
phosphorylation were still visible. Trance amounts of Akt
phosphorylation were also seen in 3T3-RON-cf cells.
Phosphorylation of p38 MAP kinase was at the minimal
level. In the case of RON160, spontaneous phosphoryla-
tion of Erk1/2, Akt, and p38 MAP kinase was observed in
3T3-RON160 cells (Fig. 3C). Zt/g4 stimulation further
enhanced the levels of phosphorylation. In contrast, elim-
ination of the C-terminus significantly reduced the phos-
phorylation levels of Erk1/2, Akt, and p38 MAP kinase in
response to Zt/g4 stimulation. As shown in Fig. 3D, the
levels of Erk1/2 phosphorylation, although still visible,
were dramatically reduced. Similarly, phosphorylation of
Akt and p38 was at the minimal level. These results,
together with those from Fig. 2, demonstrate that the C-
terminus is not only important for induced RON phos-
phorylation and spontaneous RON160 auto-phosphor-
ylation, but also essential for activation of downstream
signaling pathways. Moreover, truncation of the c-termi-
nus was unable to completely eliminate Erk1/2 phospho-
rylation.
The C-terminal tail is critical in regulating RON or RON-
160-mediated β-catenin expression
Cytoplasmic β-catenin accumulation is regulated by GSK-
3β (16). RON or RON160 inactivates GSK-3β by increas-
ing its Ser-9 phosphorylation (17,18). We wanted to
determine if elimination of the C-terminus affects RON or
RON160-meidated β-catenin accumulation. As shown in
Fig. 4A, increased β-catenin expression was observed in
RON or RON160 cells in comparison with parental 3T3
cells. However, this effect was not seen in RON-cf and
RON160-cf cells. A slight increase in β-catenin was found
in 3T3-RON160-cf cells but hardly detected in RON-cf
cells. In analyzing GSK-3β Ser-9 phosphorylation, we
found that Zt/g4 increased GSK-3β Ser-9 phosphorylation
in both 3T3-RON and RON160 cells. However, this effect
was not seen in cells expressing RON-cf or RON160-cfs
(Fig. 4B). The stimulating effects of Zt/g4 on increased
expression of β-catenin in 3T3-RON or RON160 cells but
not in 3T3-RON-cf or RON160-cf cells were also observed
in Fig. 4B. Thus, the C-terminus is important in RON/
RON160-mediated GSK-3β Ser-9 phosphorylation lead-
ing to increased stability of β-catenin in the cytoplasm.
Deletion of the C-terminus is sufficient to abolish RON or 
RON160-mediated cell proliferation, morphological 
change, and migration
Overexpression of RON or RON160 in NIH3T3 cells
resulted in increased cell proliferation, which was further
enhanced after cells were stimulated with Zt/g4 (Fig 5).
Similar results were also seen after MSP stimulation (data
not shown). However, the spontaneous and Zt/g4-
induced growth activities were completely lost in cells
which expressed RON-cf or RON160-cf. In both cases, the
numbers of cells were at the levels relatively comparable
to those of control NIH-3T3 cells. It needs to point out
that the low levels of Erk1/2 activation in RON-cf or
RON160-cf cells as shown in Fig. 3B and 3D were not suf-
ficient to cause proliferation of RON-cf and RON160-cf
cells.
Expression of RON160 but not RON often resulted in
NIH3T3 cell morphological changes such as the round up
appearance. These changes were not seen in cells express-
ing RON160-cf (Fig. 6A, top panel). Upon stimulation
with Zt/g4, cell shape changes were observed in 3T3-RON
cells. However, this effect was not seen in 3T3-RON-cf
cells (Fig. 6A, bottom panel). Stimulation of 3T3-
RON160 cells with Zt/g4 further changed cell morpholo-
gies due to the formation of focus-like cell clusters. How-
ever, these activities were not present in 3T3-RON160-cf
cells (Fig. 6A, bottom panel). In all cases, 3T3-RON-cf and
3T3-RON160-cf cells displayed typical fibroblast mor-
phologies similar to those shown by parental NIH-3T3
cells.
Spontaneous cell migration was increased in cells express-
ing RON or RON160 (Fig. 6B). However, this effect was
not observed in 3T3-RON-cf and 3T3-RON160-cf cells.
Stimulation of 3T3-RON or -RON160 cells with Zt/g4 fur-
ther enhanced cell migration. More than 70% of the open
space was covered by migrated 3T3-RON or -RON160
cells. In contrast, the migration of 3T3-RON-cf or
RON160-cf cells upon Zt/g4 treatment remained at the
levels comparable to the control 3T3 cells. These results,
together with those from Fig. 5 and 6A, demonstrate that
elimination of the C-terminus significantly diminishes
the ability of RON or RON160 to mediate cell prolifera-
tion, morphological changes, and migration.
Inability of C-terminus-free RON160 to mediate tumor 
growth in Balb/c mice
RON160 is the oncogenic variant that initiates and pro-
motes tumor growth when transfected cells were inocu-
lated into mice (Table 1). NIH3T3 cells expressing RON
do not cause tumor growth. To determine if elimination
of the C-terminus affects the RON160-mediated tumor
formation, 3T3-RON160-cf cells were inoculated into ath-
ymic nude mice and tumor growth was monitored.
Results in Table 1 show that NIH3T3 cells did not form
tumor in mice as expected. 3T3-RON160 cells formed
tumors in all 3-injected mice with a latency of 9 days. The
average sizes of tumors were 2.6 × 2.1 cm in diameter. No
tumor formation was observed in mice inoculated with
3T3-RON160-cf, indicating that RON160-cf loses the abil-
ity to initiate tumor growth in mice.Journal of Experimental & Clinical Cancer Research 2008, 27:55 http://www.jeccr.com/content/27/1/55
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Discussion
The purpose of this study was to determine the signifi-
cance of the entire C-terminus in RON or RON160-medi-
ated biological activities. The C-terminus plays the vital
role in regulating RON-mediated activities. Both positive
and negative activities have been documented [14,15],
suggesting that the functions of the C-terminus are com-
plex. Studies from previous reports have mainly focused
on identification and characterization of structural
domains in the C-terminus [14,16,28]. The role of the
entire C-terminus was often ignored or less emphasized.
For example, the sequence of -Y1353-VQLPAT-Y1360MNL-
designated as the bidentate domain in the C-terminus has
been studied in details [14,16,28]. The domain is known
as the docking site for anchoring intracellular proteins
necessary for transduction of RON signals [14,16,28].
However, this domain has the inhibitory effect on RON
kinase activities [16] and the inhibitory activity remains
strong even Y1353/Y1360 was substituted with other amino
acids [16]. This suggests the existence of additional deter-
Effect of the C-terminal truncation on RON or RON160-mediated cytoplasmic accumulation of β-catenin Figure 4
Effect of the C-terminal truncation on RON or RON160-mediated cytoplasmic accumulation of β-catenin: (A) 
Cellular proteins (50 μg/lane) from individual cell lines were subjected to Western blot analysis using rabbit IgG antibodies to 
β-catenin. (B) Cells were stimulated with Zt/g4 (2 nM) for 30 min. Cellular proteins were subjected to Western blot analysis 
using mouse IgG mAb against phosphor-Ser-9 of GSK-3β or regular GSK-3β. Expression of β-catenin was also determined. β-
actin was probed as the loading controls. Data shown here are from one of three experiments with similar results.
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minants in the C-terminus [16]. We took a function-based
approach to study the roles of the entire C-terminus in
RON or RON160-mediated biological activities. Our data
demonstrated that the C-terminus is required for ligand-
dependent RON phosphorylation, dimerization, activa-
tion of Erk1/2 and AKT, and cellular activities such as cell
proliferation and migration. The C-terminus was also crit-
ical for ligand-independent RON160 phosphorylation
and downstream signaling events. Significantly, elimina-
tion of the entire C-terminus completely blocked the
RON160-mediated tumor growth in athymic nude mice.
The RON receptor contains several functional domains
critical in ligand binding, protein maturation, and biolog-
ical activities [1,7,24]. As shown in RON160, deletion of
the first IPT domain in the extracellular sequence of the
RON β-chain results in the gain of oncogenic functions
[11,23,29]. In contrast, splicing out the last 46 amino
acids coded by exon 19 in the catalytic kinase domain cre-
ates a kinase-dead variant RON170, which is unable to
transduce signals [13]. Previous studies have defined two
functions of the C-terminal tail. One is to act as a docking
site for interaction with intracellular signaling proteins
[14]. This is mainly manifested by the bidentate tyrosine
motif [14]. Upon phosphorylation of Y1353/Y1360, the
motif serves as an anchor to recruit downstream signaling
molecules such as PI-3 kinase [16], Grb-2 [30], and others
[31]. Substitutions of Y1353/Y1360 with phenylalanine sig-
nificantly impair RON-mediated cell migration and other
activities but have no effect on MSP-induced RON phos-
phorylation at Y1238/Y1239  in the kinase domain [16].
Another function of the C-terminus is the auto-inhibitory
effect on the RON kinase activities [15]. This activity is
presumably mediated by functional domains in the C-ter-
minus that interact with the kinase catalytic domain [15].
There is evidence suggesting that the bidentate motif is
involved in interaction with the RON kinase domain.
However, substitutions of Y1353/Y1360 cannot eliminate
this effect, indicating that other determinants in the C-ter-
minus are also involved in the inhibitory effect [15]. The
results from our current studies showed that the entire C-
terminus is essential in RON auto-phosphorylation and
signal transduction. First, deletion of the C-terminus
resulted in the inability of RON to undergo tyrosine phos-
phorylation upon ligand or agonistic mAb stimulation.
Spontaneous and Zt/g4-induced phosphorylation of
RON160 were also abolished. These data suggested that
ligand-dependent or independent RON or RON160 phos-
phorylation occurred only in the presence of the C-termi-
nus. These findings are different from previous studies
showing that ligand induces RON phosphorylation in the
presence of F1353/F1360. Second, activation of downstream
signaling proteins such as Erk1/2 and ATK was dimin-
ished in cells stably expressing RON-cf. This effect
occurred also in RON160-cf cells. As shown in Fig. 6C and
6D, high levels of spontaneous and Zt/g4-enhanced Erk1/
2 or ATK phosphorylation were dramatically reduced in
RON160-cf cells, confirming that the entire C-terminus is
essential in activation of downstream signaling compo-
nents. However, it needs to point out that truncation of
the entire C-terminus cannot completely abolish MSP or
Zt/g4-induced phosphorylation of Erk1/2 and other sign-
aling proteins as shown in Fig. 6B and 6D. It is possible
that activated RON kinase by itself is capable of activating
downstream signaling events although the levels of the
activation are relatively low. Finally, the increased stabili-
zation by RON or RON160 of cytoplasmic β-catenin was
significantly impaired due to the truncation of the C-ter-
minus. The impairment was also accompanied by the ina-
bility of RON-cf or RON160 -cf in response to Zt/g4
induced GSK-3β Ser-9 phosphorylation. Cytoplasmic β-
catenin accumulation plays a role in RON or its variant-
mediated tumorigenic activities in colonic epithelial cells
[26]. In conclusion, the entire C-terminus plays a pivotal
role in controlling RON or RON160-mediated phosphor-
ylation and signaling events.
The role of the C-terminus in RON or oncogenic RON var-
iant-mediated tumorigenic activities is complex. Most of
the studies focused on the bidentate tyrosine Y1353/Y1360
[14,28]. Analysis of oncogenic mutant ROND1232V has
revealed that substitution of Y1353/Y1360 completely abol-
ishes in vitro cell-transforming activities and tumor growth
in animal models [28,32]. However, this effect was not
Effect of C-terminal truncation on RON-RON160-mediated  cell proliferation Figure 5
Effect of C-terminal truncation on RON-RON160-
mediated cell proliferation: NIH3T3 cells expressing 
RON, RON160 or others (1 × 105cells/well) were cultured 
in triplicate in a 96-well plate in DMEM with 5% FBS. Cells 
were stimulated with 2 nM of mAb Zt/g4 for 5 days. Cell 
numbers were determined as previously described [11]. 
Parental NIH3T3 cells were used as the control. Results 
shown here are from one of three experiments with similar 
results.
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Effect of C-terminal truncation on RON or RON160-mediated cell morphological change and migration Figure 6
Effect of C-terminal truncation on RON or RON160-mediated cell morphological change and migration: (A) 
Cell incubation and Zt/g4 stimulation were carried out as detailed in Fig. 5. Three days after stimulation, cells were photo-
graphed for morphological changes as previously described [23]. (B) Cell migration was determined as detailed in Materials and 
Methods. Results shown here are from one of three experiments with similar results.
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seen in cells expressing oncogenic mutant RONM1254T
[28,32]. RONM1254T continues to cause cell transforma-
tion and tumor growth even the C-terminal Y1353/Y1360
were substituted. Nevertheless, Y1353/Y1360 substitutions
have a negative impact on RONM1254T- mediated tumori-
genic activities. As shown in the focus formation and
tumor growth assays, the numbers of foci was reduced
and the tumor latency was prolonged [28]. These results
imply that the bidentate motif is involved in the onco-
genic activity of RONM1254T but is displaceable. Further
studies demonstrated that the catalytic kinase activities
play the vital role in these pathological events [28,32,33].
Considering the report showing that the synthetic peptide
containing Y1353/Y1360 or even F1353/F1360 inhibits RON
kinase activities both in vitro and in vivo [15], it is likely
that the requirement of the bidentate motif in oncogenic
RON mutant-mediated activities depends largely on the
activation status of the kinase domain. We demonstrated
that the entire C-terminus is required for RON-mediated
cell growth, migration, and morphological changes. The
C-terminus was also crucial for RON160-mediated cellu-
lar transformation and tumorigenic growth in vivo. The
function of the entire C-terminus, in the case of RON and
RON160, is not displaceable. As shown in results,
increased cell proliferation, morphological change, and
enhanced migration were diminished in cells expressing
RON-cf and RON160-cf. These changes were directly asso-
ciated with the inability of RON-cf or RON160-cf to
undergo tyrosine phosphorylation and to activate the
high levels of the downstream signaling events. Thus, the
C-terminus is an intriguing component in the RON pro-
tein. In quiescent cells, it controls RON kinase activities
through the use of the bidentate motif to interact with the
catalytic domain [15]. Such interaction seems to be neces-
sary in maintaining RON in the inactive mode. Upon lig-
and stimulation and subsequent phosphorylation at
Y1353/Y1360, the C-terminal tail is released from the cata-
lytic pocket and acts as the docking site for signaling pro-
teins [14]. The current data support this model. We
showed that the deletion of the entire C-terminus abol-
ished RON or RON160-mediated cell growth, shape
change, and migration. Moreover, it eliminated the onco-
genic potentials of RON160 acquired from the deletion of
the first IPT domain. Thus, the entire C-terminus is a vital
component of RON not only for structural integrity, but
also for biological activities. Understanding the roles of
the C-terminus should help us to gain insight into the
mechanisms by which RON or RON160 exerts its activi-
ties relevant to cancer progression.
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